ORCID Profile
0000-0003-4242-1025
Current Organisation
Anhui Medical University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Public Library of Science (PLoS)
Date: 11-05-2017
Publisher: Springer Science and Business Media LLC
Date: 09-07-2019
Publisher: Oxford University Press (OUP)
Date: 16-04-2019
DOI: 10.1136/POSTGRADMEDJ-2018-136036
Abstract: To describe association between the genetic variation of inflammation-associated gene, P2X7R, and ankylosing spondylitis (AS) susceptibility. Four single nucleotide polymorphisms (SNPs) of P2X7R gene were genotyped in 673 patients with AS and 687 healthy controls. Allele and genotype frequencies and different genetic models were performed to calculate ORs and 95% CIs, the demographic and clinical characteristics of patients were recorded. The data analyses were also conducted by sex. Compared with controls, genetic variation in rs7958311 but not the other three SNPs was statistically significant in female patients (χ2=6.907, p=0.032). Specifically, the P2X7R gene rs7958311 polymorphism A allele showed a protective effect in AS susceptibility (OR=0.704, p=0.049, pFDR=0.061). In addition, female in iduals with GA and/or AA genotypes had a lower risk of having AS compared with those with GG genotype (GA vs GG: OR=0.446, p=0.012, pFDR=0.030 AA vs GG: OR=0.440, p=0.039, pFDR=0.061 GA/AA vs GG: OR=0.445, p=0.009, pFDR=0.030). Furthermore, in iduals with A allele (ie, GA/AA vs GG) had a higher disease activity, including Bath Ankylosing Spondylitis Disease Activity Index (overall: Z=− 2.630, p=0.014 male: Z=− 2.243, p=0.025), Schober test (overall: Z=− 3.041, p& .001 male: Z=− 2.243, p=0.025) and chest expansion (overall: Z=− 3.895, p=0.004 male: Z=− 2.403, p=0.016). The allelic variation of rs7958311 SNP in P2X7R gene may have a protective effect on AS susceptibility in females and is associated with disease activity in male patients.
Publisher: Springer Science and Business Media LLC
Date: 22-08-2016
Publisher: Springer Science and Business Media LLC
Date: 21-03-2019
DOI: 10.1007/S10067-019-04505-5
Abstract: To investigate the role of methylation levels of the IFN regulatory factor 8 (IRF8) gene promoter in the development of ankylosing spondylitis (AS). In this study, we compared the methylation levels of the IRF8 gene promoter between 99 AS patients and 99 healthy controls using MethylTarget approach. Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) was performed to compare the mRNA levels of the IRF8 gene in the other 19 AS patients and 19 healthy controls. Differential methylation was found in 91 CpG sites of the IRF8 gene promoter, and 4 CpG regions were highly methylated in AS patients compared to healthy controls (p < 0.05). In the verification stage, we found that the mRNA levels of the IRF8 gene in AS patients were significantly lower than that in controls (AS 0.77 (0.39-1.74), P = 0.038). Positive correlations between methylation of the IRF8 gene and the duration of disease, BASFI, and ESR were observed in AS patients. We found a significant hypermethylation of the IRF8 gene promoter and a downregulation of the mRNA levels of the IRF8 gene in AS patients. This suggests that aberrant methylation of the IRF8 gene promoter may probably contribute to the development and pathogenesis of AS through regulating the expression of mRNA.
Publisher: Springer Science and Business Media LLC
Date: 25-03-2019
DOI: 10.1007/S00223-019-00542-Z
Abstract: Various studies have investigated the serum sclerostin and bone morphogenetic protein-2 (BMP-2) levels in patients with ankylosing spondylitis (AS), but the results were inconsistent. The aim of this meta-analysis was to synthetically assess the associations of serum levels of sclerostin and BMP-2 with AS. Multiple electronic databases were searched to locate relevant articles published before November 2018. Pooled standard mean difference (SMD) with 95% confidence interval (CI) was calculated by the random-effect model. Totally, 21 studies were included. Meta-analysis results showed no significant difference between AS group and control group in serum sclerostin levels (SMD = 0.098, 95% CI - 0.395 to 0.591, p = 0.697). Nevertheless, serum BMP-2 levels in AS patients were higher than that in controls (SMD = 1.184, 95% CI 0.209 to 2.159, p = 0.017). Subgroup analysis demonstrated that European and South American AS patients had lower serum levels of sclerostin than controls. AS patients with age ≥ 40 years, erythrocyte sedimentation rate (ESR) ≤ 20 mm/h and Bath Ankylosing Spondylitis Functional Index (BASFI) < 4 had statistically significant lower serum sclerostin concentrations compared to controls. Chinese and Korean AS patients as well as patients with lower CRP had higher serum BMP-2 levels than controls, and country may be a source of heterogeneity across the studies. No publication bias existed and sensitivity analysis confirmed the stability of results. Serum BMP-2, but not sclerostin levels may be closely related to the development of AS.
Publisher: Wiley
Date: 26-09-2018
Publisher: Wiley
Date: 06-05-2023
DOI: 10.1002/ACR.25127
Abstract: To investigate the relationship between sleep disturbance, catastrophizing, and knee pain in middle‐aged and older in iduals. Data from the Osteoarthritis Initiative cohort from months 48 to 96 were used, where month 48 was treated as baseline. Knee pain (Western Ontario and McMaster Universities Osteoarthritis Index pain scale score ≥5 [range 0–20]), catastrophizing (extracted from Coping Strategies Questionnaire score ≥3 [range 0–6]), and sleep quality (extracted from Center for Epidemiologic Studies Depression Scale [range 1–4]) were assessed annually. We described the association of sleep disturbance with the presence and risk of knee pain and catastrophizing. The mediation effect of knee pain and catastrophizing on the sleep–catastrophizing and sleep–pain association was evaluated, respectively. Catastrophizing and knee pain were reported in 346 (10%) and 917 (24%) of the 3,813 participants (mean 64.9 years, 58% female) at baseline. Participants with worse sleep disturbance were more likely to have knee pain (prevalence ratio [PR] 1.4–2.0, P for trend .001) and catastrophizing (PR 1.4–3.1, P for trend .001). Sleep disturbance at baseline predicted the risk of knee pain (risk ratio [RR] 1.1, P for trend .001) and catastrophizing (RR 1.2–1.7, P for trend .001) during follow‐up. No statistically significant interactions between sleep disturbance and knee pain or catastrophizing were observed. Knee pain and catastrophizing mediated the sleep–catastrophizing and sleep–pain association, respectively, at baseline, and knee pain negatively mediated the sleep–catastrophizing association longitudinally. Sleep disturbance was associated with the presence and risk of catastrophizing and knee pain. Sleep interventions may have a universal and independent effect in preventing incident knee pain.
Publisher: Oxford University Press (OUP)
Date: 10-07-2023
DOI: 10.1093/PM/PNAD097
Abstract: Frailty is a multisystem syndrome and its relationship with symptomatic osteoarthritis has been reported. We aimed to identify trajectories of knee pain in a large prospective cohort and to describe the effect of frailty status at baseline on the pain trajectories over 9 years. We included 4419 participants (mean age 61.3 years, 58% female) from the Osteoarthritis Initiative cohort. Participants were classified as “no frailty,” “pre-frailty,” or “frailty” at baseline, based on 5 characteristics (ie, unintentional weight loss, exhaustion, weak energy, slow gait speed, and low physical activity). Knee pain was evaluated annually using the Western Ontario and McMaster Universities Osteoarthritis Index pain subscale (0–20) from baseline to 9 years. Of the participants included, 38.4%, 55.4%, and 6.3% were classified as “no frailty,” “pre-frailty,” and “frailty,” respectively. Five pain trajectories were identified: “No pain” (n = 1010, 22.8%), “Mild pain” (n = 1656, 37.3%), “Moderate pain” (n = 1149, 26.0%), “Severe pain” (n = 477, 10.9%), and “Very Severe pain” (n = 127, 3.0%). Compared to participants with no frailty, those with pre-frailty and frailty were more likely to have more severe pain trajectories (pre-frailty: odds ratios [ORs] 1.5 to 2.1 frailty: ORs 1.5 to 5.0), after adjusting for potential confounders. Further analyses indicated that the associations between frailty and pain were mainly driven by exhaustion, slow gait speed, and weak energy. Approximately two-thirds of middle-aged and older adults were frail or pre-frail. The role of frailty in predicting pain trajectories suggests that frailty may be an important treatment target for knee pain.
Publisher: Wiley
Date: 07-2023
DOI: 10.1002/JCLA.24945
Abstract: Glucocorticoids (GCs) were the essential drugs for systemic lupus erythematosus (SLE). However, different patients differ substantially in their response to GCs treatment. Our current study aims at investigating whether climate variability and climate‐gene interaction influence SLE patients' response to the therapy of GCs. In total, 778 SLE patients received therapy of GCs for a study of 12‐week follow‐up. The efficacy of GCs treatment was evaluated using the Systemic Lupus Erythematosus Disease Activity Index. The climatic data were provided by China Meteorological Data Service Center. Additive and multiplicative interactions were examined. Compared with patients with autumn onset, the efficacy of GCs in patients with winter onset is relatively poor (OR adj = 1.805, 95%CI adj : 1.181–3.014, p adj = 0.020). High mean relative humidity during treatment decreased the efficacy of GCs (OR adj = 1.033, 95%CI adj : 1.008–1.058, p adj = 0.011), especially in female (OR adj = 1.039, 95%CI adj : 1.012–1.067, p adj = 0.004). There was a significant interaction between sunshine during treatment and TRAP1 gene rs12597773 on GCs efficacy (Recessive model: AP = 0.770). No evidence of significant interaction was found between climate factors and the GR gene polymorphism on the improved GCs efficacy in the additive model. Multiplicative interaction was found between humidity in the month prior to treatment and GR gene rs4912905 on GCs efficacy (Dominant model: OR = 0.470, 95%CI: 0.244–0.905, p = 0.024). Our findings suggest that climate variability influences SLE patients' response to the therapy of GCs. Interactions between climate and TRAP1/GR gene polymorphisms were related to GCs efficacy. The results guide the in idualized treatment of SLE patients.
Publisher: Elsevier BV
Date: 10-2019
DOI: 10.1016/J.CCA.2019.07.038
Abstract: We investigated the characterization of the gut microbiome in Chinese patients with ankylosing spondylitis (AS) and healthy controls (HCs) and to explore the association ofbacteria communities with dietary factors and disease activity. 16S ribosomal RNA gene sequencing was performed on fecal DNA isolated from stool s les in consecutive cross-sectional cohorts. Alpha and beta ersities were assessed using QIIME, and comparisons were performed using one-way ANOVA, Student's t-test, and SKN multiple range comparisons to examine differences between groups and a correlation network analysis was performed. We investigated 207 s les from 103 AS patients and 104 HCs. Alpha ersity was not significant difference in AS compared with HCs. For the community structure, Bacteroidetes was the most represented class. Megamonas, Dorea, and Blautia were significantly greater in AS than in HCs, whereas the abundance of Lachnospira, Ruminococcus, and Clostridium_XlVb was significantly lower in AS than in HCs. In addition, Specific gut microbiome was significantly correlated with disease activity and dietary factors. Our results suggest that the human gut microbiome of AS patients was clearly different from that of HCs and bacteria communities are associated with dietary factors and disease activity.
No related grants have been discovered for Faming Pan.